ENvue Medical said the Nasdaq Hearings Panel denied its request to continue listing on the Nasdaq Capital Market. Trading in its common stock will be suspended and is scheduled to begin on OTC Markets under the symbol FEED on September 16, 2026. Shares fell 69.25% to close at $1.03 in regular trading and declined another 23.20% to $0.79 after hours. The company said the decision does not affect its operations, products, customers or ongoing commercial activities. ENvue remains focused on commercializing its ENvue Navigation System, PainShield and UroShield, while evaluating Nasdaq procedures and alternatives, including a further appeal. Its market capitalization was $951.43 thousand, and the stock had fallen 98.88% over the past year.